Check-Cap Ltd (NASDAQ:MBAI) Short Interest Update

Check-Cap Ltd (NASDAQ:MBAI) saw a significant drop in short interest in August. As of August 14th, there was short interest totaling 26,875 shares, a drop of 71.9% from the July 30th total of 95,679 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average trading volume of 27,346 shares, the days-to-cover ratio is currently 1.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Check-Cap in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Check-Cap currently has an average rating of “Sell”.

Check-Cap Trading Down 3.1%

NASDAQ:MBAI traded down $0.21 during trading hours on Thursday, hitting $6.57. 14,919 shares of the stock were exchanged, compared to its average volume of 144,859. The firm’s fifty day moving average price is $8.22 and its 200 day moving average price is $10.45. Check-Cap has a 52-week low of $4.35 and a 52-week high of $27.44. The company has a market cap of $9.03 million, a P/E ratio of -0.47 and a beta of 0.68.

Check-Cap Company Profile

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.